AGP Executive Report
Last update: 9 hours agoDrug Safety Recall: Taiwan’s TFDA ordered a recall of 5,152 vials of Sandoz’s Omnitrope Sandoz injection (growth disorder drug) after broken vial necks were reported; the batch (PR7349) must be fully recalled by Aug. 8, with corrective actions required. COVID-19 Update (Taiwan): Taiwan’s CDC says the COVID-19 wave is rising again, with emergency cases jumping 117.4% week-on-week and severe cases increasing; officials warn emergency patients could reach about 51,000 around Aug. 16 if the trend continues. TB Diagnostics (Taiwan): IntelliGenome appointed Yu Shing Bio-Tech as exclusive distributor in Taiwan to commercialize a CRISPR-TB blood test and support TFDA registration plus a multicenter clinical validation study led by Taipei Veterans General Hospital. Infectious Disease Alerts (Region): Korea’s KDCA issued guidance for travelers as dengue and measles spread across Southeast Asia, urging people to check vaccination status and local outbreaks before trips. Health Tech Manufacturing (Taiwan): THY Precision highlighted its ISO-certified cleanroom capabilities for medical injection molding and device assembly, targeting higher regulatory compliance needs from global healthcare firms. Geopolitics & Health Access (Taiwan): Taiwan suspended spot LNG purchases from Papua New Guinea after PNG closed Taiwan’s Port Moresby office, affecting about 500,000 tonnes of spot supply. Women’s Health & Safety Context: A new Women, Peace and Security index ranks Northern Europe highest for women’s inclusion, justice, and security, with Taiwan listed among the top 30.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.